Fig. 5From: Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trialPrimary endpoint: Least square mean of the change in the 1/SCr time slopeBack to article page